Ferraiuolo R, Stoppelli M P, Verde P, Bullock S, Lazzaro P, Blasi F, Pietropaolo T C
J Cell Physiol. 1984 Nov;121(2):368-74. doi: 10.1002/jcp.1041210214.
A cell line derived from a human kidney carcinoma produces in vitro the urinary type of plasminogen activator (urokinase). The synthesis of plasminogen activator is enhanced by 12-O-tetradecanoyl-phorbol-13-acetate(TPA); the increase can be followed both in the cell lysate and in the culture medium. The effect requires RNA and protein synthesis as well as the continuous presence of the inducer. Immunofluorescence and immunoprecipitation experiments with monospecific antiurokinase IgG show that kidney carcinoma cells synthesize a 50,000-dalton urokinase and TPA enhances the synthesis of the same molecular species. Hybridization of the total cellular RNA to a human urokinase cDNA probe shows that TPA increases the urokinase mRNA level.
源自人肾癌的细胞系在体外产生尿激酶型纤溶酶原激活剂（尿激酶）。12 - O - 十四烷酰佛波醇 - 13 - 乙酸酯（TPA）可增强纤溶酶原激活剂的合成；这种增加在细胞裂解物和培养基中均可观察到。该效应需要RNA和蛋白质合成以及诱导剂的持续存在。用单特异性抗尿激酶IgG进行的免疫荧光和免疫沉淀实验表明，肾癌细胞合成一种50,000道尔顿的尿激酶，TPA可增强同一分子种类的合成。将总细胞RNA与人尿激酶cDNA探针杂交表明，TPA可增加尿激酶mRNA水平。
